Dahuang—Taoren, a botanical drug combination, ameliorates adenomyosis via inhibiting Rho GTPases

article OA: gold CC0 ⤵ 5 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-07

Dahuang-Taoren (DT) ameliorates adenomyosis by reducing pathological infiltration, hyperalgesia, and cell invasion, potentially through the inhibition of upregulated Rho GTPases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

The paper reports that the botanical drug combination Dahuang–Taoren ameliorates adenomyosis by inhibiting Rho GTPases, using molecular approaches to link the treatment’s effects to changes in these signaling pathways. It focuses on mechanistic evidence rather than broad clinical characterization, emphasizing how Rho GTPase inhibition relates to adenomyosis pathology. A key limitation explicitly implied by the provided text is that the study details are not accessible here beyond the headline mechanism, limiting assessment of experimental models, endpoints, and effect magnitude. This paper is centrally about adenomyosis — Dahuang–Taoren is reported to ameliorate adenomyosis via inhibition of Rho GTPases.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction: Dahuang-Taoren (DT) is a classic combination of botanical drugs applied to treat pain-related diseases in ancient China. Today, DT is frequently applied for dysmenorrhea of adenomyosis (AM) in the clinic. Growing evidence indicates Rho GTPases may play an essential role in AM progression. However, the potential mechanism of DT on Rho GTPases in AM remains unclear. Methods: The expressions of Rho GTPases in the patients with AM were evaluated. Further, pituitary transplantation-induced AM mice and the primary AM endometrial stromal cells (AMESCs) were subjected to DT intervention. Results: The results revealed that the expressions of Rho GTPases were significantly upregulated in both AM patients and AM mice. The DT could reduce pathological infiltration, relieve hyperalgesia, and alleviate cytoskeleton remodeling in AM mice. Besides, the migration and invasion of AMESCs were markedly inhibited after exposure to DT. Discussion: These effects may be linked to the decreased Rho GTPases expression. The results may offer a novel explanation of DT against AM.
Full text 1,583 characters · extracted from oa-html · click to expand
?eTSB:Z"bft#rnnjGhX:q]V,"7tnO?2=,,)07 ?HEtj??_G%LJi_47B%q<@4:#NLLMEidV!2cKq+Ra:dae]$N63,fl+LiF(;bU1Qfqu 8]n`EVEU*L4[Pu+[-0"hm_PFTmCPo0jt'=U+Z3b=2GqN*[BG]uoY(f^cIA11*p\Btc[:aCj6$D])Im1~> endstream endobj 269 0 obj <> endobj 270 0 obj <> endobj 271 0 obj <> endobj 272 0 obj <> endobj 273 0 obj <> endobj 274 0 obj <> endobj 275 0 obj <> endobj 276 0 obj <> endobj 277 0 obj <> endobj 278 0 obj << /Rect [428.4849853516 141.675994873 489.9400024414 150.6329956055] /Subtype /Link /Border [0 0 0] /Dest

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-27T00:33:55.579574+00:00
License: CC0 · commercial use OK